Australia is experience innovative medication for excess weight: Retatrutide. This new dual agonist – working on both GLP-1 and GIP receptors – has significant efficacy in international trials, suggesting meaningful decreases in BMI. While availability is pending with Australian regulators, a number of individuals dealing with obesity might vie